Mono Omega 650 EC (60 Capsules)


Clinical Applications
• Positively Affects the Production of Arachidonic Acid-Derived
• Supports Cardiovascular Health*
• Supports Healthy Mental Functioning*
• Supports Healthy Glucose and Insulin Metabolism*
• By Supplying the Precursors EPA and DHA, Helps the Body
Generate Specialized Proresolving Lipid Mediators, Such as
Resolvins and Protectins*

The MonoOmega 650 family of formulas feature MaxSimil® monoglyceride fish oil that has a three times greater EPA+DHA absorption rate than an equivalent dose of other leading fish oils. Through the use of MaxSimil patented lipid absorption enhancement technology (PLATform), the fish oil is absorption-ready and can be directly assimilated in the intestinal tract for maximum benefit. *

Take one softgel daily, or use as directed by your healthcare practitioner.
Consult your healthcare practitioner prior to use. Individuals taking blood thinners or other medication should discuss potential interactions with their healthcare practitioner. Do not use if tamper seal is damaged.

Does Not Contain
Wheat, gluten, corn, yeast, soy protein, dairy products, shellfish, peanuts, tree nuts, egg, ingredients derived from genetically modified organisms (GMOs), artificial colors, artificial sweeteners, or artificial preservatives.

SKU: 1205 Category:


MaxSimil® Patented Lipid Absorption Enhancement Technology (PLATform)
The MaxSimil PLATform is a novel monoglyceride delivery system that enhances absorption of lipid-based
and lipid-soluble nutraceutical and food ingredients. This technology has been applied to Arthritis Center of
Riverside’s MonoOmega 650 formulas in order to create a unique vehicle by which to deliver EPA and DHA.
Due to the fact that monoglyceride oils are intrinsically emulsifiers and are, by nature, in a readily absorbable
form, they can bypass the body’s normal fat digestion process. These qualities make MonoOmega 650 an
excellent method for delivering omega-3 fatty acids, especially to individuals with digestive, pancreatic, or gall
bladder challenges. Studies show that MaxSimil fish oils (FO) have three times (300%) greater absorption of
EPA and DHA compared to other leading fish oils.*[1-3]

MonoOmega 650 formulas are made using proprietary MaxSimil compositions containing monoglyceride FO
with no additional ingredients, carriers, or excipients. Each fish-gelatin softgel is enteric-coated, and every
batch of fish oil ensure the world’s highest standards for purity, potency, and freshness. The fish oil is non-
GMO, certified sustainable from Scandinavia, and antibiotic-free. Additionally, it is eco-friendly because the
greater absorption of EPA and DHA ultimately means that fewer grams of fish oil need to be harvested for the
same benefit.*

In Vitro and In Vivo Animal Studies
The ability of MaxSimil-enhanced EPA and DHA to positively influence growth inhibition and apoptosis in
colorectal, breast, lung, and prostate diseased cell lines was first demonstrated in a series of in vitro studies.
[4-6] Researchers subsequently set out to demonstrate efficacy in animal models after oral administration. In
three separate animal models, MaxSimil EPA and DHA forms showed superior activity on diseased cell-line
growth inhibition and cytokine production when compared to control, corn oil, krill oil, or the parent forms ethyl
ester (EE) EPA and ethyl ester (EE) DHA.[4,7,8] These in vivo animal studies proved that orally supplemented
MaxSimil EPA and DHA were well-absorbed and bioactive. Researchers postulated that the observed superior
effects of MaxSimil EPA and DHA forms were the result of enhanced absorption, and they set out to prove this

Preclinical Bioavailability Studies
The in vivo pharmacokinetic studies in rodents involved a comparison between MaxSimil DHA FO and its
parent EE DHA FO and an analysis of blood concentrations of DHA over time. The doses used were equivalent
to human doses of 3 g/day and 30 g/day; the latter was included primarily to investigate toxicity at high doses.
Researchers found that MaxSimil DHA FO had a three times (3x) higher peak concentration, a 3x higher
saturation potential at the high dose, and a 3x higher absorption rate (at a 3 g/day equivalent human dose)
than its parent DHA FO. No toxicity was observed at either dose level.[1,2] This research demonstrated superior
bioavailability and presumably better exposure of cells to DHA.*

Clinical Bioavailability Study
A phase 1, double-blind, randomized, crossover, pharmacokinetic study was performed in 20 healthy adults
aged between 19 and 71 years who were administered 6 g (containing 1800 mg EPA and 1200 mg DHA) per
day of EE FO or MaxSimil FO.[3] Parameters studied were plasma EPA and DHA concentration (as percent of
total fatty acids), Cmax, and AUC. Compared to EE EPA+DHA, the results indicated that at peak concentration,
MaxSimil EPA and DHA forms were 3x higher, they reached maximum concentration faster, and maintained
their plasma levels longer. The finding in the animal study was validated: the MaxSimil FO instantaneous
absorption was 3x greater than the EE form. Likewise, the AUC over 24 hours was also more than 3x higher
(P<.0001) for MaxSimil EPA and DHA (MaxSimil FO).*

Not only did this study confirm the bioavailability findings in the animal study, but it also demonstrated that after
24 hours, the MaxSimil FO maintained 2-3x higher blood levels of EPA and DHA than the EE FO. This means
that, given a daily dose, circulating EPA and DHA levels can be expected to ramp up over time and remain
high with steadily increasing exposure of cells to EPA, DHA, and their metabolites. Based on the results of the
bioavailability studies, an individual would get more EPA and DHA from MaxSimil FO than from EE FO gram
for gram. Furthermore, as shown in the animal studies, one could anticipate enhanced effects. It is noteworthy
that all 20 adults who completed the study saw their omega-3 absorption enhanced when taking the MaxSimil
enhanced FO.*

Expanding Research
In vitro and animal studies have demonstrated the positive effects of MaxSimil FO on airway immune response
(e.g., IgE, leukocytes); the expression of COX-2, NF-kB, cytokines (e.g., IL-6, IL-8), MUC5AC, and mucin; and
Ca(2+) hypersensitivity in lung tissues.[8-11] In other research, rats subjected to eight weeks of a high-fat, highcarbohydrate
diet were either not supplemented or provided 3 g/day of MaxSimil DHA. Compared to the data
from the non-supplemented group, the data from the MaxSimil DHA supplemented group clearly showed a
positive impact on cardiovascular health parameters. Measures included blood pressure, heart rate, serum lipid
levels, cytokine production, aortic wall thickness, and a DHA:AA ratio in aortic tissue, which correlated with the
production of resolvin D2 and D3 metabolites.*[12]
A Note About Resolvins and Other EPA and DHA Metabolites
Specialized proresolving lipid mediators, such as resolvins, protectins, and maresins, are EPA and DHA
metabolites naturally produced in vivo through enzymatic conversion of EPA and DHA. These mediators aid
the body’s “clean-up” response to the arachidonic acid cascade.[13] Rather than supplying a single molecule or
metabolite, which would mirror the pharmaceutical model, MonoOmega 650 fish oils provide all the benefits of
EPA and DHA as well as the expected and desirable benefits of their metabolites.*

Arthricor®: MonoOmega 650 MD
Each softgel of MonoOmega 650 MD provides 500 mg of MaxSimil FO combined with 50 mg of Arthricor olive
leaf extract. It is generally accepted that the Mediterranean diet is beneficial to cardiovascular health,[14-16] and
research suggests that olive oil and its phenolic constituents are primary contributors.[17-21] Taking Arthricor olive
leaf extract daily provides the polyphenolic benefits of eating five olives or 50 mL of olive oil each day. Phenolic
compounds, as found in Arthricor, have been shown to have a protective effect against LDL oxidation.[19,22,23]
Arthricor provides three polyphenols—hydroxytyrosol, oleuropein, and tyrosol—for maximum benefit.*

1. Unpublished, internal data. Ingenutra.
2. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Compositions comprising polyunsaturated fatty acid monoglycerides or
derivatives thereof and uses thereof. US patent 8,198,324. June 12, 2012.
3. MaxSimil Patented Lipid Absorption Technology Clinical Study Report: MaxSimil® 3020 Omega-3. Sherbrooke (Québec), Canada: Ingenutra; 2015. [Unpublished,
internal data]
4. Morin C, Rousseau É, Fortin S. Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins Leukot
Essent Fatty Acids. 2013 Sep;89(4):203-13. [PMID: 23932824]
5. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US
patent 8,119,690. February 21, 2012.
6. Fortin S, inventor; Centre de Recherche sur les Biotechnologies Marines, assignee. Polyunsaturated fatty acid monoglycerides, derivatives, and uses thereof. US
patent 8,329,747. December 11, 2012.
7. Morin C, Blier PU, Fortin S. Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to
resolve inflammation in a rheumatoid arthritis model. Arthritis Res Ther. 2015 May 29;17:142. [PMID: 26022389]
8. Morin C, Fortin S, Cantin AM, et al. Docosahexaenoic acid derivative prevents inflammation and hyperreactivity in lung: implication of PKC-Potentiated inhibitory
protein for heterotrimeric myosin light chain phosphatase of 17 kD in asthma. Am J Respir Cell Mol Biol. 2011 Aug;45(2):366-75. [PMID: 21057106]
9. Morin C, Fortin S, Cantin AM, et al. MAG-EPA resolves lung inflammation in an allergic model of asthma. Clin Exp Allergy. 2013 Sep;43(9):1071-82. [PMID:
10. Morin C, Cantin AM, Rousseau É, et al. Pro-resolving action of MAG-DHA in lung inflammatory models related to cystic fibrosis. Am J Respir Cell Mol Biol. 2015
Oct;53(4):574-83. [PMID: 25781052]
11. Morin C, Fortin S, Rousseau É. New omega-3 derivatives reduce airway inflammation and prevent rho-kinase activation in an allergic model of asthma. J Aller
Ther. 2012;3(S1):003. doi:10.4172/2155-6121.S1-003.
12. Morin C, Rousseau E, Blier PU, et al. Effect of docosahexaenoic acid monoacylglyceride on systemic hypertension and cardiovascular dysfunction. Am J Physiol
Heart Circ Physiol. 2015 Jul 1;309(1):H93-H102. [PMID: 25910811]
13. Weylandt KH, Chiu CY, Gomolka B, et al. Omega-3 fatty acids and their lipid mediators: towards an understanding of resolvin and protectin formation.
Prostaglandins Other Lipid Mediat. 2012 Mar;97(3-4):73-82. [PMID: 22326554]
14. Guasch-Ferré M, Hu FB, Martínez-González MA, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013 Apr
4;368(14):1279-90. [PMID: 23432189]
15. Mayor S. Mediterranean diet reduces cardiovascular events in people with heart disease, study shows. BMJ. 2016 Apr 24;353:i2348. [PMID: 27114468]
16. Chiva-Blanch G, Badimon L, Estruch R. Latest evidence of the effects of the Mediterranean diet in prevention of cardiovascular disease. Curr Atheroscler Rep.
2014 Oct;16(10):446. [PMID: 25115436]
17. Fitó M, Cladellas M, de la Torre R, et al. Anti-inflammatory effect of virgin olive oil in stable coronary disease patients: a randomized, crossover, controlled trial.
Eur J Clin Nutr. 2008 Apr;62(4):570-74. [PMID: 17375118]
18. Ruano J, López-Miranda J, de la Torre R, et al. Intake of phenol-rich virgin olive oil improves the postprandial prothrombotic profile in hypercholesterolemic
patients. Am J Clin Nutr. 2007 Aug;86(2):341-46. [PMID: 17684203]
19. Gimeno E, de la Torre-Carbot K, Lamuela-Raventós RM, et al. Changes in the phenolic content of low density lipoprotein after olive oil consumption in men. A
randomized crossover controlled trial. Br J Nutr. 2007 Dec;98(6):1243-50. [PMID: 17617938]
20. Bogani P, Galli C, Villa M, et al. Postprandial anti-inflammatory and antioxidant effects of extra virgin olive oil. Atherosclerosis. 2007 Jan;190(1):181-86. [PMID:
21. Guasch-Ferré M, Hu FB, Martínez-González MA, et al. Olive oil intake and risk of cardiovascular disease and mortality in the PREDIMED Study. BMC Med. 2014
May 13;12:78. [PMID: 24886626]
22. Castañer O, Covas MI, Khymenets O, et al. Protection of LDL from oxidation by olive oil polyphenols is associated with a downregulation of CD40-ligand
expression and its downstream products in vivo in humans. Am J Clin Nutr. 2012 May;95(5):1238-44. [PMID: 22440854]
23. Raederstorff D. Antioxidant activity of olive polyphenols in humans: a review. Int J Vitam Nutr Res. 2009 May;79(3):152-65. [PMID: 20209466]

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.